Colorectal Cancer Trial, Recruiting NCT06641310 Sponsor: University of Michigan Rogel Cancer Center Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT06641310
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with Familial Adenomatous Polyposis (FAP) — either confirmed by a genetic test showing an APC gene mutation, or by a clinical diagnosis involving more than 50 growths (polyps) in the large bowel
  • People who still have their rectum (the lower part of the large bowel) intact — either before bowel surgery or after bowel surgery where the rectum was kept
  • People who have at least 5 rectal polyps larger than 2 mm, confirmed by a recent camera examination of the lower bowel
  • People who have had no sign of invasive cancer for at least 6 months before screening, and who are at least 6 months past any cancer treatment (such as surgery, chemotherapy, immunotherapy, hormone therapy, or radiation)
  • People who have not started daily use of anti-inflammatory medications (such as sulindac or celecoxib) within 3 months before the study starts, and who do not use them frequently during the study
  • People who have not started weight-loss medications (such as semaglutide, liraglutide, tirzepatide, or orlistat) within 3 months before the study starts, and who do not use them during the study
  • Adults aged 18 years or older
  • People living with HIV who are on effective treatment and have had an undetectable level of the virus in the last 6 months
  • People with a history of chronic hepatitis B infection whose virus levels are undetectable while on appropriate treatment
  • People with a history of hepatitis C who have been treated and cleared of the infection, or who are currently on treatment with an undetectable virus level
  • People on long-term antiviral medication for herpes simplex virus (HSV)
  • Women who could become pregnant and who agree to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) for the full duration of the study and until the final endoscopy is completed — and who agree to inform the study team immediately if pregnancy occurs or is suspected
  • People who are currently inactive, defined as doing 60 minutes or less of moderate or vigorous exercise per week over the past month (as measured by a standard questionnaire)
  • People who have no known reasons preventing them from starting a regular exercise program (as assessed by a standard health questionnaire called the PAR-Q+)
  • People who have enough space in their home to fit a treadmill for the study period, or who already have access to a suitable treadmill (for example, through a gym membership) approved by the study's exercise specialist
  • People whose home can have exercise equipment delivered and set up by the study team (this does not apply if an outside treadmill is being used)
  • People with internet or Wi-Fi access at home (those without internet may be provided with a pre-paid tablet device)
  • People who are willing and able to attend scheduled visits, follow treatment plans, and complete all required study activities
  • People who have received approval from their doctor to participate
  • People who are able to understand the study and are willing to sign a written consent form

Who may not be able to join:

  • People who have had their entire rectum and colon surgically removed (total proctocolectomy)
  • People whose biopsy at screening shows high-grade abnormal cell changes or cancer
  • People who have had radiation treatment to the pelvic area
  • People currently taking part in another clinical trial involving an experimental treatment
  • People with serious uncontrolled medical conditions, including severe heart failure, unstable chest pain, irregular heart rhythms, or mental health or personal circumstances that would make it difficult to follow the study requirements
  • People with severe, ongoing, or poorly controlled conditions affecting the kidneys, urinary system, liver, blood, hormones, heart, blood vessels, lungs, joints, nerves, mental health, or metabolism
  • People who are pregnant, as camera examinations of the bowel are not recommended during pregnancy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Michigan Rogel Cancer Center
Registry
ClinicalTrials.gov
Start date
13 May 2026
Est. completion
1 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Exercise therapy compliance (feasibility)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov